Newsletter | October 8, 2019

10.08.19 -- Tips For Solving Oral Technology Challenges

Revolutionizing Allergy Therapy

ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis, and treatment of allergies. Previously, all of its marketed allergen immunotherapies were delivered by injection, resulting in a limited patient population and reduced patient adherence. By adding a new drug delivery solution, ALK-Abelló saw a marked improvement in patient tolerability, preference, and compliance.

Solvents, Polymers, And Cyclones: Bioavailability Enhancement Through Spray-Dried Dispersions

Very few new molecular entities in active clinical development are readily bioavailable, and, when dosed at escalated levels, even these may not be sufficiently absorbed. Learn how spray-dried amorphous dispersion might help.

Pediatric Drug Delivery: Challenges And Solutions

Arguably the biggest challenge in pediatric oral solid formulation development is to develop flexible dosage forms with measurable and easy to administer dosage, preferably formulated with taste-masking properties for better acceptance of the drug formulation in children. This Q&A session with formulation and bioavailability experts addresses formulation challenges for pediatric populations and how they are overcoming them.

Real-World Dosing Solutions For Patients

Explore how a fast-dissolve technology can provide dosing solutions for various patient population groups. Whether you are considering an ODT to enhance pharmacokinetics through pre-gastric absorption, looking for a way to improve patient compliance, or seeking a marketing advantage for a valued brand, this technology solution can help enhance the value of your investment and accelerate a product’s potential.